PARP PET
A PET tracer that measures how much of the DNA repair enzyme PARP a tumour has, to predict response to PARP inhibitors.
18F-FluorThanatrace (FTT, Penn) and 18F-PARPi (MSK) image PARP1 expression and drug engagement. Trials in ovarian, breast, and head-and-neck cancer test whether uptake predicts PARP-inhibitor benefit beyond BRCA/HRD status.
How it works
Radiolabelled olaparib or rucaparib analogues bind PARP1 in the nucleus.
- Direct pharmacodynamic readout
- Complements genomic HRD
- Research stage
- Limited to a few academic sites
Latest papers
topQuery for this technology: (TITLE:"PARP PET" OR ABSTRACT:"PARP PET" OR TITLE:"18F-FluorThanatrace" OR ABSTRACT:"18F-FluorThanatrace" OR TITLE:"PARP imaging" OR ABSTRACT:"PARP imaging"). Results are unfiltered search hits about PARP PET, not a curated reading list.
Pages like this
not linked directly; found by shared links- PairingPlatinum chemotherapy in HRD tumours
Shares DNA damage response & homologous recombination, Ovarian cancer, Triple-negative breast cancer (TNBC).
- PersonSusan M. Domchek
Shares Abramson Cancer Center, University of Pennsylvania, PARP, Ovarian cancer, Triple-negative breast cancer (TNBC).
- CompanyRefleXion Medical
Shares Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET, PET (positron emission tomography).
- TechnologyPET/MRI
Shares Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET, PET (positron emission tomography).
- PersonAlan Ashworth
Shares PARP, Ovarian cancer, Triple-negative breast cancer (TNBC).
- ProductRucaparib
Shares Base excision repair, PARP & alkylation damage, PARP, Ovarian cancer.
- IdeaWhich patients' blood clones will become leukaemia after treatment?
Shares DNA damage response & homologous recombination, PARP, Ovarian cancer.
- TrialATHENA-MONO / GOG-3020
Shares PARP, Ovarian cancer.